MaxCyte, Inc. (MXCT) Profit Breakdown
- 2026-06-30: Cell Engineering Technology $5.60M.
- 2025-06-30: Cell Engineering Technology $6.99M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2019-12-31 to 2026-06-30
- Data captured
Profit by product
Gross profit: each quarter (3 month)
| Quarter end | Cell Engineering Technology |
|---|---|
| 2026-06-30 | $5.60M |
| 2025-06-30 | $6.99M |
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Cell Engineering Technology |
|---|---|
| 2026-06-30 | -$8.87M |
| 2025-06-30 | -$12.36M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |